(Q38159716)

29 August 2017

title

Targeting the Janus kinases in rheumatoid arthritis: focus on tofacitinib (English)

1 reference

29 August 2017

0 references

Kunihiro Yamaoka

1

1 reference

29 August 2017

Yoshiya Tanaka

series ordinal

2

1 reference

29 August 2017

language of work or name

English

0 references

publication date

5 November 2013

1 reference

Expert Opinion on Pharmacotherapy

29 August 2017

published in

1 reference

29 August 2017

volume

15

1 reference

29 August 2017

issue

1

1 reference

29 August 2017

page(s)

103-113

1 reference

The pathogenesis of rheumatoid arthritis

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.854771

Inflammatory bone loss: pathogenesis and therapeutic intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.854771

Intensive treatment and treatment holiday of TNF-inhibitors in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.854771

Next stage of RA treatment: is TNF inhibitor-free remission a possible treatment goal?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.854771

Treating rheumatoid arthritis to target: recommendations of an international task force

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.854771

Phosphorylation and activation of the Jak-3 Janus kinase in response to interleukin-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.854771

Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.854771

Interaction of IL-2R beta and gamma c chains with Jak1 and Jak3: implications for XSCID and XCID

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.854771

Mutations in severe combined immune deficiency (SCID) due to JAK3 deficiency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.854771

Changes in synovial tissue Jak-STAT expression in rheumatoid arthritis in response to successful DMARD treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.854771

Expression of Jak3, STAT1, STAT4, and STAT6 in inflammatory arthritis: unique Jak3 and STAT4 expression in dendritic cells in seropositive rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.854771

The Sequence of the Human Genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.854771

21 January 2018

The Janus kinases (Jaks)

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.854771

Prevention of Organ Allograft Rejection by a Specific Janus Kinase 3 Inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.854771

Multiplexed mass cytometry profiling of cellular states perturbed by small-molecule regulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.854771

The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon-γ and interleukin-17 production by human CD4+ T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.854771

Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.854771

A quantitative analysis of kinase inhibitor selectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.854771

Effects of JAK3 inhibition with CP-690,550 on immune cell populations and their functions in nonhuman primate recipients of kidney allografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.854771

Immunosuppression by the JAK3 inhibitor CP-690,550 delays rejection and significantly prolongs kidney allograft survival in nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.854771

Dissecting specificity in the Janus kinases: the structures of JAK-specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.854771

From systemic T cell self-reactivity to organ-specific autoimmune disease via immunoglobulins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.854771

Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.854771

Regulation of inflammatory responses in tumor necrosis factor-activated and rheumatoid arthritis synovial macrophages by JAK inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.854771

IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.854771

The JAK inhibitor CP-690,550 (tofacitinib) inhibits TNF-induced chemokine expression in fibroblast-like synoviocytes: autocrine role of type I interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.854771

Selectivity and therapeutic inhibition of kinases: to be or not to be?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.854771

Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.854771

Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.854771

Lack of effect of tofacitinib (CP-690,550) on the pharmacokinetics of the CYP3A4 substrate midazolam in healthy volunteers: confirmation of in vitro data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.854771

The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.854771

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.854771

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.854771

Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.854771

10.1517/14656566.2014.854771

21 January 2018

Identifiers

DOI

1 reference

29 August 2017

1 reference